Home Latest Articles
Latest Articles
  • Wenjia YIN, Lihua HUANG, Fuliang XIONG, Ming ZHANG, Chuan SHI
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1247-1253.

    The sucrose pill cores were sequentially coated with a drug layer, an isolation layer, and an enteric layer to prepare the enteric-coated pellets loaded with escin from Suoluozi(Semen Aesculi) by bottom spray coating in a fluidized bed. A single factor test combined with a multi-index comprehensive evaluation method was adopted to optimize the formulation of enteric-coated pellets with the drug loading rate, yield, process feasibility, total escin content, and release amount within 2 h in acidic media as the evaluation indicators. Three batches of Suoluozi enteric-coated pellets were prepared according to the optimal formulation. The average particle size, bulk density, friability and total escin content of the enteric-coated pellets were 665.26 μm, 0.92 g/mL, below 2.5%, and (101.30±0.79)%, respectively. After filling the obtained enteric-coated pellets into the capsules, an in vitro release test was carried out. The results showed that the release amount of enteric-coated pellet-based capsules within 2 h in acidic media was (5.26±2.25)%, but the drug was basically completely released in phosphate buffer(pH 6.8) in 45 min.

  • Yinchun DING, Jihui TANG
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1254-1258.

    The formulation of rufinamide(1) tablets were optimized in this paper. The release curves of 1 tablets in 0.1 mol/L hydrochloric acid and phosphate buffer(pH 6.8) were drawn. The parameters, namely the proportion of filling agent, adhesive agent amount and type, and disintegrating agent amount, were optimized by evaluating the similarity of release curves between the self-made tablets and the reference preparation. The results showed that the optimized composition of a tablet was 200.00 mg of 1, 50.00 mg of lactose, 66.75 mg of microcrystalline cellulose PH101,20.00 mg of corn starch, 6.50 mg of HPMC K4M, and 10.00 mg of cross-linked sodium carboxymethyl cellulose. The release test results showed that the release curves between the optimized self-made tablets and the reference preparation were similar. In addition, the optimal tablets produced in a pilot-scale was rather stable within 6 months.

  • Siyao ZHANG, Yi LIANG
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1259-1264.
  • Xinzhu NA, Junlin ZHANG, Yuxi HU
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1265-1268.
  • Qian WANG, Haoyu YANG, Feng JIANG, Shengming WANG, Kan TIAN, Shiyu XIE
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1269-1272.
  • Yi WU, Jingwen HE, Rong JIANG, Rong SHAO
    Chinese Journal of Pharmaceuticals. 2023, 54(8): 1273-1277.
  • Xu QIN, Zhenbo TONG, Hongxian REN
    Chinese Journal of Pharmaceuticals. 2023, 54(7): 984-992.

    Inhalation therapy is the superior choice for treating respiratory diseases. Unlike traditional methods of drug administration, inhalation therapy requires the use of inhalation devices to deliver the drugs to targeted areas. Innovations in inhalation devices aim to improve the delivery efficiency, reduce the impact of respiratory flow rate on drug delivery and improve patient compliance. This paper reviews the development trends of oral inhalation devices and their progress in intelligentization. The soft mist inhaler based on innovative microfluidic nebulization technology and its nebulization mechanism and delivery characteristics are analyzed and discussed. Moreover, this paper further elaborates on the different stages of the development of intelligent inhalation devices. The impact of intelligent inhalation devices on patient compliance is also discussed, providing a reference for further research on intelligent inhalation devices.

  • Junyan GUO, Wenzhe WU, Jian WANG
    Chinese Journal of Pharmaceuticals. 2023, 54(7): 993-1001.

    In recent years, pulmonary infectious diseases have posed a serious threat to human health. Compared with the traditional oral and injection administration routes, inhalation administration is increasingly used to treat pulmonary infectious diseases. This route can achieve targeted delivery of drugs to the infected sites, and has the advantages of improving the pulmonary bioavailability, reducing systemic adverse reactions and drug resistance, and therefore has gained widely concern. This paper summarizes the research progress of inhalation preparations for treatment of pulmonary infectious diseases, with a view to providing references for the research and development of anti-infective drugs for pulmonary inhalation.

  • Yifei TANG, Jie GAO, Qi ZHANG, Junyan GUO, Hongli KONG, Wenzhe WU
    Chinese Journal of Pharmaceuticals. 2023, 54(7): 1002-1007.

    Unlike traditional dry powder inhalers that provide directly inhalable drug-containing powders, the electrical heating vaporization inhalation device vaporizes the drug through rapid heating, then makes the drug cool in the inspiratory airflow to form aerosol to be inhaled. Therefore, it is critical to control the degree of drug degradation in the process of vaporization and ensure that the formed aerosol has good delivery efficiency. This study was conducted by the self-made rapid heating and adjustable electrical heating vaporization device with edaravone(with low melting point and boiling point) and risperidone(with high melting point and boiling point) as the model drugs. The stainless steel sheet material, drug-coating layer thickness and heating vaporization temperature were optimized to control thermal degradation and improve delivery efficiency. The results showed that the purity of risperidone aerosol could be significantly increased from 39.31% to 95.77% after the stainless steel sheet was treated at 500 ℃ for 30 min. Edaravone with drug loading of 1.9 mg had high emitted doses and aerosol purity(above 99.8%) at the vaporization temperatures of 311 and 357 ℃. At the vaporization temperature of 357 ℃, risperidone with a drug loading of 0.5 mg also showed high emitted doses and aerosol purity. And the fine particle fraction(FPF) of both model drugs through electrical heating vaporization inhalation were over 95%, indicating good lung delivery characteristics.

  • Yuxiao SHI, Xiaohong LU, Wangding LU, Huafei LUO
    Chinese Journal of Pharmaceuticals. 2023, 54(7): 1008-1019.

    As a new biological material, exosomes have the characteristics of specificity, presentation, tumor-promoting, immune escape and induction, which are being widely used in clinical medicine. However, the specific molecular mechanism has not yet been clarified. Due to the unclear side effects of exosomes in functional applications, balancing the interests of exosomes is the key to use exosomes for treatment and diagnosis effectively. At the same time, it is necessary to simplify and improve the separation and extraction technologies of exosomes, increase production and reduce costs in order to realize the industrial production and application. It is a core to find a way to obtain high purity specific exosomes and ensure production supply. In this manuscript, the basic information, the biological function characteristics of exosomes, and the preparation process of engineering exosomes are summarized. In addition, the technologies and products from relevant commercial companies in this filed are sorted out, which provides insights to further explore the application of exosomes.

News